Catalent acquires CDMO Paragon Bioservices for $1.2bn
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Intra-Biotech Deal
- Acquisition of Private Biotech
- Includes Contract
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.